ORKA insider buying and SEC filings, explained
Oruka Therapeutics, Inc. · CIK 907654
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$777K
Planned sales (10b5-1)
$39.3M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Nov 2, 2026 | Planned (10b5-1) | Lawrence Otto Klein (CEO and Director) sold 25,000 shares at about $95.60 ($2.4M), marked as a 10b5-1 plan trade. Holdings down 3% to 923,128 shares. | SEC filing Filed Nov 2, 2026, 5:46 PM ET |
| Oct 20, 2026 | Planned (10b5-1) | Paul T Quinlan (General Counsel) sold 9,000 shares at about $78.53 ($707K), marked as a 10b5-1 plan trade. Holdings down 23% to 29,995 shares. | SEC filing Filed Oct 20, 2026, 8:42 PM ET |
| Oct 15, 2026 | Planned (10b5-1) | Joana Goncalves (Chief Medical Officer) sold 7,000 shares at about $74.81 ($524K), marked as a 10b5-1 plan trade. Holdings down 18% to 31,771 shares. | SEC filing Filed Oct 15, 2026, 6:15 PM ET |
| Oct 12, 2026 | Planned (10b5-1) | Arjun Agarwal (Senior Vice President, Finance) sold 9,999 shares at about $80.60 ($806K), marked as a 10b5-1 plan trade. Holdings down 41% to 14,219 shares. | SEC filing Filed Oct 13, 2026, 4:34 PM ET |
| Oct 1, 2026 | Planned (10b5-1) | Lawrence Otto Klein (CEO and Director) sold 25,000 shares at about $83.62 ($2.1M), marked as a 10b5-1 plan trade. Holdings down 3% to 923,128 shares. | SEC filing Filed Oct 2, 2026, 7:54 PM ET |
| Sep 21, 2026 | Planned (10b5-1) | Arjun Agarwal (Senior Vice President, Finance) sold 533 shares at $95.75 ($51K), marked as a 10b5-1 plan trade. Holdings down 4% to 14,219 shares. | SEC filing Filed Sep 21, 2026 |
| Sep 21, 2026 | Planned (10b5-1) | Paul T Quinlan (General Counsel) sold 10,000 shares at about $93.64 ($936K), marked as a 10b5-1 plan trade. Holdings down 25% to 29,995 shares. | SEC filing Filed Sep 21, 2026 |
| Sep 15, 2026 | Planned (10b5-1) | Joana Goncalves (Chief Medical Officer) sold 7,947 shares at about $92.38 ($734K), marked as a 10b5-1 plan trade. Holdings down 20% to 31,771 shares. | SEC filing Filed Sep 15, 2026 |
| Sep 15, 2026 | Sale | Lawrence Otto Klein (CEO and Director) sold 2,452 shares at $95.71 ($235K). Holdings down <1% to 923,128 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 15, 2026 |
| Sep 15, 2026 | Sale | Paul T Quinlan (General Counsel) sold 1,039 shares at $95.71 ($99K). Holdings down 3% to 29,995 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 15, 2026 |
| Sep 15, 2026 | Sale | Laura Lee Sandler (President / COO) sold 906 shares at $95.71 ($87K). Holdings down <1% to 235,478 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 15, 2026 |
| Sep 11–15, 2026 | Planned (10b5-1) | Arjun Agarwal (Senior Vice President, Finance) sold 10,019 shares between Sep 11 and Sep 15 at about $92.42 ($926K), marked as a 10b5-1 plan trade. Holdings down 40% to 14,752 shares. | SEC filing Filed Sep 15, 2026 |
| Sep 1, 2026 | Planned (10b5-1) | Laura Lee Sandler (President / COO) sold 5,000 shares at about $91.82 ($459K), marked as a 10b5-1 plan trade. Holdings down 2% to 236,384 shares. | SEC filing Filed Sep 1, 2026 |
| Sep 1, 2026 | Planned (10b5-1) | Lawrence Otto Klein (CEO and Director) sold 75,000 shares at about $91.84 ($6.9M), marked as a 10b5-1 plan trade. Holdings down 7% to 925,580 shares. | SEC filing Filed Sep 1, 2026 |
| Aug 17, 2026 | Planned (10b5-1) | Joana Goncalves (Chief Medical Officer) sold 7,000 shares at about $111.84 ($783K), marked as a 10b5-1 plan trade. Holdings down 18% to 32,718 shares. | SEC filing Filed Aug 17, 2026 |
| Aug 14, 2026 | Planned (10b5-1) | Paul T Quinlan (General Counsel) sold 52,000 shares at about $108.49 ($5.6M), marked as a 10b5-1 plan trade. Holdings down 63% to 31,034 shares. | SEC filing Filed Aug 14, 2026 |
| Aug 13, 2026 | Planned (10b5-1) | Arjun Agarwal (Senior Vice President, Finance) sold 10,000 shares at about $106.66 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 40% to 15,312 shares. | SEC filing Filed Aug 14, 2026 |
| Jul 15, 2026 | Planned (10b5-1) | Joana Goncalves (Chief Medical Officer) sold 7,000 shares at about $86.28 ($604K), marked as a 10b5-1 plan trade. Holdings down 18% to 32,718 shares. | SEC filing Filed Jul 15, 2026 |
| Jul 13, 2026 | Planned (10b5-1) | Arjun Agarwal (Senior Vice President, Finance) sold 9,999 shares at about $84.63 ($846K), marked as a 10b5-1 plan trade. Holdings down 40% to 15,312 shares. | SEC filing Filed Jul 13, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Laura Lee Sandler (President / COO) sold 5,000 shares at about $94.42 ($472K), marked as a 10b5-1 plan trade. Holdings down 2% to 236,384 shares. | SEC filing Filed Jul 1, 2026 |
| Jun 22, 2026 | Planned (10b5-1) | Arjun Agarwal (Senior Vice President, Finance) sold 1,587 shares at about $80.95 ($128K), marked as a 10b5-1 plan trade. Holdings down 9% to 15,312 shares. | SEC filing Filed Jun 22, 2026 |
| Jun 15, 2026 | Planned (10b5-1) | Joana Goncalves (Chief Medical Officer) sold 7,947 shares at about $69.28 ($551K), marked as a 10b5-1 plan trade. Holdings down 20% to 32,718 shares. | SEC filing Filed Jun 15, 2026 |
| Jun 15, 2026 | Sale | Lawrence Otto Klein (CEO and Director) sold 1,729 shares at $69.69 ($120K). Holdings down <1% to 925,580 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 15, 2026 |
| Jun 15, 2026 | Sale | Laura Lee Sandler (President / COO) sold 600 shares at $69.69 ($42K). Holdings down <1% to 236,384 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 15, 2026 |
| Jun 15, 2026 | Sale | Paul T Quinlan (General Counsel) sold 733 shares at $69.69 ($51K). Holdings down 2% to 31,034 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 15, 2026 |
| Jun 12–15, 2026 | Planned (10b5-1) | Arjun Agarwal (Senior Vice President, Finance) sold 9,854 shares between Jun 12 and Jun 15 at about $69.72 ($687K), marked as a 10b5-1 plan trade. Holdings down 37% to 16,899 shares. | SEC filing Filed Jun 15, 2026 |
| Jun 11–12, 2026 | Planned (10b5-1) | Carl Dambkowski (Director) sold 35,000 shares between Jun 11 and Jun 12 at about $70.12 ($2.5M), marked as a 10b5-1 plan trade. Holdings down 47% to 38,743 shares. | SEC filing Filed Jun 12, 2026 |
| May 21, 2026 | Planned (10b5-1) | Carl Dambkowski (Director) sold 105,000 shares at about $58.97 ($6.2M), marked as a 10b5-1 plan trade. Holdings down 59% to 73,743 shares. | SEC filing Filed May 22, 2026 |
| May 18, 2026 | Planned (10b5-1) | Arjun Agarwal (Senior Vice President, Finance) sold 10,290 shares at about $59.07 ($608K), marked as a 10b5-1 plan trade. Holdings down 39% to 16,406 shares. | SEC filing Filed May 18, 2026 |
| May 15, 2026 | Planned (10b5-1) | Joana Goncalves (Chief Medical Officer) sold 7,000 shares at about $61.85 ($433K), marked as a 10b5-1 plan trade. Holdings down 17% to 33,377 shares. | SEC filing Filed May 15, 2026 |
| May 1, 2026 | Planned (10b5-1) | Laura Lee Sandler (President / COO) sold 5,000 shares at about $63.88 ($319K), marked as a 10b5-1 plan trade. Holdings down 2% to 236,984 shares. | SEC filing Filed May 1, 2026 |
| Apr 15, 2026 | Planned (10b5-1) | Joana Goncalves (Chief Medical Officer) sold 7,000 shares at about $66.12 ($463K), marked as a 10b5-1 plan trade. Holdings down 17% to 33,377 shares. | SEC filing Filed Apr 15, 2026 |
| Mar 16, 2026 | Sale | Lawrence Otto Klein (CEO and Director) sold 1,729 shares at $41.30 ($71K). Holdings down <1% to 927,309 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 17, 2026 |
| Mar 16, 2026 | Sale | Arjun Agarwal (Senior Vice President, Finance) sold 395 shares at $41.30 ($16K). Holdings down 2% to 18,863 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 17, 2026 |
| Mar 16, 2026 | Sale | Laura Lee Sandler (President / COO) sold 600 shares at $41.30 ($25K). Holdings down <1% to 236,984 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 17, 2026 |
| Mar 16, 2026 | Planned (10b5-1) | Joana Goncalves (Chief Medical Officer) sold 7,641 shares at about $40.91 ($313K), marked as a 10b5-1 plan trade. Holdings down 19% to 33,377 shares. | SEC filing Filed Mar 17, 2026 |
| Mar 16, 2026 | Sale | Paul T Quinlan (General Counsel) sold 733 shares at $41.30 ($30K). Holdings down 2% to 31,767 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 17, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Laura Lee Sandler (President / COO) sold 5,000 shares at about $33.56 ($168K), marked as a 10b5-1 plan trade. Holdings down 2% to 237,584 shares. | SEC filing Filed Mar 2, 2026 |
| Feb 17, 2026 | Planned (10b5-1) | Joana Goncalves (Chief Medical Officer) sold 7,000 shares at about $32.36 ($227K), marked as a 10b5-1 plan trade. Holdings down 17% to 34,018 shares. | SEC filing Filed Feb 17, 2026 |
| Jan 15, 2026 | Planned (10b5-1) | Joana Goncalves (Chief Medical Officer) sold 7,000 shares at about $31.81 ($223K), marked as a 10b5-1 plan trade. Holdings down 82% to 1,518 shares. | SEC filing Filed Jan 16, 2026 |
| Jan 2, 2026 | Planned (10b5-1) | Laura Lee Sandler (President / COO) sold 13,000 shares at about $28.52 ($371K), marked as a 10b5-1 plan trade. Holdings down 6% to 205,084 shares. | SEC filing Filed Jan 2, 2026 |
| Dec 19, 2025 | Planned (10b5-1) | Joana Goncalves (Chief Medical Officer) sold 7,000 shares at about $30.61 ($214K), marked as a 10b5-1 plan trade. Holdings down 82% to 1,518 shares. | SEC filing Filed Dec 19, 2025 |
43 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ORKA in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.